Surprisingly rapid regrowth of unused brain connections after decades of near blindness
Since 2007, clinical trials using gene therapy have resulted in often-dramatic sight restoration for dozens of children and adults who were otherwise doomed to blindness. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children’s Hospital of Philadelphia (CHOP), have found evidence that this sight restoration leads to strengthening of visual pathways in the brain, published this week in Science Translational Medicine.
“The patients had received the gene therapy in just one eye (their worse seeing eye), and though we imaged their brains only about two years later, on average, we saw big differences between the side of the brain connected to the treated region of the injected eye and the side connected to the untreated eye,” said lead author Manzar Ashtari, PhD, director of CNS Imaging at the Center for Advanced Retinal and Ocular Therapeutics in the Department of Ophthalmology at Penn. Ashtari is the former director of Diffusion Tensor Image Analyses and Brain Morphometry at CHOP.
“It’s an elegant demonstration that these visual processing pathways can be restored even long after the period when it was thought there would be a loss of plasticity,” said senior author Jean Bennett, MD, PhD, the F.M. Kirby Professor of Ophthalmology at Penn and director of the Center for Advanced Retinal and Ocular Therapeutics.
The team examined ten patients who have Leber’s congenital amaurosis Type 2 (LCA2), a rare disease that afflicts those who inherit a bad copy of an LCA2 gene from each parent, LCA2 causes their retinas to degenerate slowly and they typically have limited visual function at birth and then experience progressive loss of their remaining vision, rendering them completely blind by mid-life.
In one of the first great success stories for gene therapy, Bennett’s team and others demonstrated the effectiveness of LCA2 gene augmentation in animal tests stretching back to the early 2000s. The basic strategy is to inject a harmless virus that inserts good copies of the normal LCA2 gene into retinal cells. Patients who have received the gene therapy have commonly gone from being blind or near blind to being partially sighted and able to navigate almost normally.
One question hanging over the field has been: even if retinal function improves, how well can the brain’s visual processing pathways recover, after years of near-total blindness in which those unused pathways inevitably will have weakened?
Ashtari, a neuroimaging specialist, addressed this question with several experiments. First she compared the LCA2 group, which had initially received the gene therapy in one eye for safety reasons, to an age-matched control group with normal vision.
Using an advanced method of MRI technique to uncover deep brain connections, she found that while the connectivity of the visual pathway from the treated eye in LCA2 patients was similar to that of sighted controls, the untreated eye showed weaker connectivity to the brain as compared to the connections for the treated side. The data showed that the retina-brain pathways in the treated eyes in the LCA2 group seemed nearly as robust as the corresponding pathways in the sighted control group, implying that these pathways had largely rebuilt themselves in the LCA2 patients, following their retinal intervention.
“That was what we expected to see— the more the treated eye sees the world and interacts with the environment the more it stimulates the pathway and the stronger the connecting pathway becomes between the retina and the brain,” said Ashtari.
The result came despite the fact that many of the LCA2 patients were in their 20s, and one was even 45—an age when the ability of the nervous system to rewire itself is thought to be greatly reduced.
Ashtari also found a strong hint in the data that the treated-eye pathways tended to be in better shape when more time had elapsed since the treatment, implying that these pathways continue to improve with use. By contrast, the untreated-eye pathways showed a clear decline with time.
The Latest on: Vision-Restoring Gene Therapy
via Google News
The Latest on: Vision-Restoring Gene Therapy
- Children's Hospital Los Angeles treats first patient on the west coast using gene therapyon March 21, 2018 at 11:59 am
Approximately one week later, the patient returns to have the procedure performed on their second eye. The vision-restoring RPE65 gene therapy, marketed as LUXTURNA™, was developed by Spark ...
- Children’s Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapyon March 20, 2018 at 5:00 pm
The vision-restoring RPE65 gene therapy, marketed as LUXTURNA™, was developed by Spark Therapeutics. The procedure gained marketing approval from the U.S. Food and Drug Administration in 2017 for both ...
- Is the $850,000 price tag for a blindness-curing gene therapy a sign of future medical costs?on January 2, 2018 at 4:00 pm
has just revealed the new therapy will cost $850,000. Gene therapies are an undeniably exciting new frontier for medicine. From Kymriah's genetically modified, cancer-hunting immune cells, to Luxturna ...
- Foundation Fighting Blindness Celebrates Historic FDA Approval of First Gene Therapy to Treat Blindnesson December 19, 2017 at 10:26 am
The Foundation was an important early investor in LUXTURNA, providing $10 million in critical seed funding for the therapy. The groundbreaking treatment is the first gene therapy for the eye and for ...
- This Gene Therapy Can Restore Vision, but Will It Break the Bank?on November 8, 2017 at 6:41 pm
In October, Spark Therapeutics (NASDAQ: ONCE) took another step closer to FDA approval for its vision-restoring drug, Luxturna. An approval for the gene-editing therapy early next year would be a big ...
- This Gene Therapy Can Restore Vision, but Will It Break the Bank?on November 8, 2017 at 5:56 pm
Luxturna is a gene therapy to treat patients with vision loss from biallelic RPE65 mutation-associated retinal dystrophy. It's administered by subretinal injection, and in trials, it's been shown to ...
- This Gene Therapy Can Restore Vision, but Will It Break the Bank?on November 7, 2017 at 4:00 pm
Quotes delayed at least 15 minutes. Real-time quotes provided by BATS BZX Real-Time Price. Market Data provided by Interactive Data (Terms & Conditions). Powered and Implemented by Interactive Data ...
via Bing News